Abbvie Inc (ABBV): FDA approves Rinvoq for Crohn’s disease:...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	833
Posts	119891
Boards Moderated	17
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 721

Thursday, 05/18/2023 3:42:57 PM

Thursday, May 18, 2023 3:42:57 PM

FDA approves Rinvoq for Crohn’s disease:

https://finance.yahoo.com/news/u-fda-approves-rinvoq-upadacitinib-162500452.html

Rinvoq now has seven FDA–approved indications: RA; psoriatic arthritis; ankylosing spondylitis; axial spondyloarthritis; ulcerative colitis; and Crohn’s disease. In the five non-IBD indications (all except UC and Crohn’s), Rinvoq is indicated for second-line treatment following a TNF-a biologic.

ABBV now has three of the four IBD approvals it seeks: Rinvoq in UC and Crohn’s, and Skyrizi in Crohn’s. Based on phase-3 data (#msg-171517753), ABBV plans to submit a Skyrizi BLA for UC in 2023.

ABBV expects combined sales of Skyrizi and Rinvoq to teach $17.5B in 2025 and $21B in 2027 (#msg-170905881).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”